Aeglea Biotherapeutics

Closed portfolio with an early-phase archive tilt

According to ClinicalTrials.gov-derived indexes, Aeglea Biotherapeutics sits in the upper quartile of US sponsors by registered trial count (#1,806 of 15,742 sponsors by registered trial count).

7 total trials none currently recruiting 6 completed early-phase tilt upper quartile by trial count

Aeglea Biotherapeutics: 7 sponsored US clinical trials, none currently recruiting.

Aeglea Biotherapeutics sponsors 7 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 6 completed. 1 of these trials are in Phase 3-4 (later-stage) and 6 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is Arginase I Deficiency, with 1 trials.

Upper-quartile sponsor footprint

Aeglea Biotherapeutics sits in the upper quartile of the sponsor corpus (#1,806 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

7 total, page 1 of 1

TERMINATED Phase 1

A Multiple Ascending Dose Study of ACN00177 (Pegtarviliase) in Subjects With CBS Deficiency

NCT05154890
COMPLETED Phase 3

Efficacy and Safety of Pegzilarginase in Patients With Arginase 1 Deficiency

NCT03921541
COMPLETED Phase 1

Pegzilarginase and Pembrolizumab for Extensive Disease Small Cell Lung Cancer

NCT03371979
COMPLETED Phase 2

A Study of AEB1102 (Pegzilarginase) in Patients With Arginase I Deficiency

NCT03378531
COMPLETED Phase 2

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With AML or MDS

NCT02732184
COMPLETED Phase 1

A Phase 1/2 Study of AEB1102 in Patients With Arginase I Deficiency

NCT02488044
COMPLETED Phase 1

A Multiple Dose, Dose Escalation Trial of AEB1102 in Patients With Advanced Solid Tumors

NCT02561234

Phase Distribution

PhaseTrial count
Phase 1 4
Phase 2 2
Phase 3 1

Therapeutic Areas

Arginase I Deficiency 1
Hyperargininemia 1

How the Aeglea Biotherapeutics early-phase archive is shaped

7 indexed studies, none listed as recruiting (0% open); 6 completed (86%).

Phase mix: 1 late (III/IV) vs 6 early (I/II) (early-phase heavy).

Top condition: Arginase I Deficiency (1 trial), 1 other listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Aeglea Biotherapeutics: archived-pipeline peers nationwide

Peers matched on 7 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Aeglea Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%10%20%30%40% Total trials Recruiting share Aeglea Biotherapeutics3M4Life Research89bioAbbott Diagnostics Division10xBio22nd Century Group23andMe3-C Institute for Social Development
Aeglea Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Aeglea Biotherapeutics sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 7 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Aeglea Biotherapeutics page

7 registered trials is a research-attention snapshot, not an endorsement of Aeglea Biotherapeutics or any single study.

  • None of Aeglea Biotherapeutics's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Arginase I Deficiency is the condition Aeglea Biotherapeutics studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Arginase I Deficiency trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Aeglea Biotherapeutics pipeline card: 7 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.